Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Viatris (VTRS)
NASDAQ:VTRS
Holding VTRS?
Track your performance easily
VTRS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.93 - $13.62
Previous CloseN/A
Volume2.11M
Average Volume (3M)9.52M
Market Cap
$13.54B
Enterprise Value$27.98B
Total Cash (Recent Filing)$998.80M
Total Debt (Recent Filing)$15.20B
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Mar 03, 2025EPS Estimate
0.58Last Dividend Ex-Date
Nov 22, 2024Dividend Yield4.23%
Share Statistics
EPS (TTM)-0.74
Shares Outstanding1,193,592,900
10 Day Avg. Volume9,694,091
30 Day Avg. Volume9,523,874
Standard Deviation0.10
R-Squared0.26
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.90
Price to Cash Flow (P/CF)4.10
P/FCF Ratio3.80
Enterprise Value/Market Cap2.07
Enterprise Value/Revenue1.86
Enterprise Value/Gross Profit4.35
Enterprise Value/Ebitda11.28
Forecast
1Y Price Target
$13.25Price Target Upside17.26% Upside
Rating ConsensusHold
Number of Analyst Covering5
Viatris News
PremiumCompany Announcements
Viatris Elects Directors and Amends Stock Plan at Meeting
PremiumCompany Announcements
Viatris Inc. Reports Strong Q3 2024 Performance
Bulls Say, Bears Say
Bulls Say
Financial StrategyViatris plans to be more aggressive with buybacks, supported by its financial flexibility and a substantial amount of free cash flow.
Market PerformanceManagement is confident about the company's performance in China, which has exceeded initial expectations.
Product DevelopmentThe company's pipeline and diversification, with a significant number of new product submissions annually, provide visibility into sustainable revenue growth.
Bears Say
Financial PerformanceThe company faces sequential headwinds in the fourth quarter, with expected declines in sales and EBITDA.
Growth ProspectsViatris has limited potential for upward revisions and lacks clinical catalysts for 2025, which affects its growth prospects.
Strategic DecisionsViatris' decision to focus on capital allocation and avoid early-stage deals may result in missing out on innovative assets that could change its financial profile.
---
Ownership Overview
0.16% Insiders
23.29% Mutual Funds
0.20% Other Institutional Investors
46.44% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VTRS FAQ
What was Viatris’s price range in the past 12 months?
Viatris lowest stock price was $9.93 and its highest was $13.62 in the past 12 months.
What is Viatris’s market cap?
Viatris’s market cap is $13.54B.
When is Viatris’s upcoming earnings report date?
Viatris’s upcoming earnings report date is Mar 03, 2025 which is in 44 days.
How were Viatris’s earnings last quarter?
Viatris released its earnings results on Nov 07, 2024. The company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.677 by $0.073.
Is Viatris overvalued?
According to Wall Street analysts Viatris’s price is currently Undervalued.
Does Viatris pay dividends?
Viatris pays a Quarterly dividend of $0.476 which represents an annual dividend yield of 4.23%. See more information on Viatris dividends here
What is Viatris’s EPS estimate?
Viatris’s EPS estimate is 0.58.
How many shares outstanding does Viatris have?
Viatris has 1,193,592,900 shares outstanding.
What happened to Viatris’s price movement after its last earnings report?
Viatris reported an EPS of $0.75 in its last earnings report, beating expectations of $0.677. Following the earnings report the stock price went up 13.565%.
Which hedge fund is a major shareholder of Viatris?
Currently, no hedge funds are holding shares in VTRS
---
Viatris Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$13.25 (17.26% Upside)
$13.25 (17.26% Upside)
Blogger Sentiment
Bullish
VTRS Sentiment 88%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 9.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $294.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.66%
12-Months-Change
Fundamentals
Return on Equity
-4.35%
Trailing 12-Months
Asset Growth
-8.18%
Trailing 12-Months
Company Description
Viatris
Viatris Inc. is a global healthcare company headquartered in Canonsburg, Pennsylvania. Formed in 2020 through the merger of Mylan and Pfizer’s Upjohn division, Viatris provides a wide range of medicines, including branded drugs, generics, biosimilars, and over-the-counter products. The company operates in over 165 countries and serves patients across numerous therapeutic areas, including infectious diseases, cardiovascular health, and oncology. Viatris also offers patient support programs and works with healthcare systems to address medical needs worldwide.
---
VTRS Company Deck
---
VTRS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong financial performance with consistent operational revenue growth and strategic debt reduction. The company is focused on expanding its innovative portfolio, particularly in cardiovascular and ophthalmology sectors. While there are challenges related to the ARV generics supply chain and certain brand declines, the overall outlook remains positive with plans for shareholder value maximization and disciplined business development.Read More>---
VTRS Net sales Breakdown
60.12% Developed Markets
16.58% Emerging Markets
14.04% Greater China
9.26% JANZ
---
VTRS Stock 12 Month Forecast
Average Price Target
$13.25
▲(17.26% Upside)
Technical Analysis
Teva Pharmaceutical
―
Perrigo Company
―
Dr Reddy's Laboratories
―
Amneal Pharmaceuticals
―
AbbVie
―
Eli Lilly & Co
―
Best Analysts Covering VTRS
1 Year
1 Year Success Rate
4/19 ratings generated profit
1 Year Average Return
-9.71%
reiterated a sell rating 2 months ago
Copying Balaji Prasad's trades and holding each position for 1 Year would result in 21.05% of your transactions generating a profit, with an average return of -9.71% per trade.
---